779 results on '"Roblin X."'
Search Results
2. AB1493 PATIENT SATISFACTION AND EXPERIENCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR WITH HIGH CONCENTRATION AND CITRATE-FREE: RESULTS FROM A MULTICENTRIC PROSPECTIVE REAL-LIFE STUDY
3. Immunomonitoring du rituximab appliqué aux maladies auto-immunes : une aide pour la pratique clinique ?
4. P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study
5. P807 HLA type impact on immunization and efficacy of ustekinumab in IBD patients: a multicenter study
6. P437 Feasibility study of a Point-of-Care assay for rapid determination of anti-TNFα biologics in capillary blood
7. P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
8. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
9. P602 Risankizumab levels but not IL22 are significantly correlated and predictive of clinical and biochemical remission in Crohn's disease
10. Laboratory Evaluation, Including Novel Diagnostic Markers
11. Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes
12. Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
13. P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
14. P494 Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
15. OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
16. P537 Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study
17. P144 Impact of major medication discontinuation during the first wave of COVID-19 pandemic on the risk of early relapse in patients with inflammatory bowel disease: a French observational retrospective study
18. P682 Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patients
19. P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study
20. Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn’s Disease?
21. Long‐term efficacy and safety of ustekinumab in 122 refractory Crohnʼs disease patients: a multicentre experience
22. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
23. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
24. DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study
25. Letter: thiopurines ‐ is less really more? Authors’ reply
26. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authorsʼ reply
27. P573 Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseases
28. P366 The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
29. P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physiciansʼ practice
30. P310 Development of a new clinico-biological score associated with disease activity in patients with inflammatory bowel disease treated with thiopurine
31. P254 Relationship between severe endoscopic lesions and plasmatic and fecal infliximab levels in acute severe ulcerative colitis: a case control study
32. P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis
33. DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohnʼs disease
34. DOP027 Long-term efficacy and safety of ustekinumab in refractory Crohnʼs disease patients: a multicenter retrospective experience
35. DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
36. OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohnʼs disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
37. How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study
38. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
39. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study
40. Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study
41. Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
42. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis
43. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
44. P439 Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn’s disease
45. P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients
46. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
47. P249 Serum calprotectin is useful to confirm Inflammatory Bowel Disease activity but is not effective to predict relapse
48. P262 Decreased infliximab trough levels (TLI) is a moderate predictor of loss of response to IFX in IBD patients
49. P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis
50. P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.